Home|Journals|Articles by Year|Audio Abstracts
 

Original Research

Egypt. J. Exp. Biol. (Zoo.). 2006; 2(0): 55-60


CD4 AND CD8 T CELL RESPONSIVENESS IN CHRONIC HEPATITIS C PATIENTS WITH OR WITHOUT SCHISTOSOMIASIS

Saber A. Sakr Gamal Badra Ayman EL-Kenawy Asmaa El-Bendary.




Abstract

The combined viral hepatitis and schistose-miasis incidence was found to be increasing; however scarce studies are available which investigated the influence of Schistosoma mansoni on the HCV specific immune respo-nse. This study included four groups: Group 1 included 23 patients infected with chronic HCV, Group 2 included 10 patients infected with Schistosoma mansoni, Group 3 included 21 patients infected with chronic HCV and Schistosoma mansoni, Group 4 included 10 healthy controls. HCV-specific CD4+ and CD8+ T cell responses were measured by flow cytometery in all groups and correlated with PCR level. The infected patients with chronic HCV alone had stronger CD4+ T cell response than did coinfected patients also the coinfected patients had the lowest percent of CD8+ T cell, and significantly higher HCV-RNA titers. An inverse relationship between virus load and CD4+ T cell responses were found. Schistosomiasis is one of the mechanisms which lead to viral persistence through down regulation of immune response and accelerate liver damage in HCV patients.

Key words: Schistosoma mansoni, CD4+, CD8+ T cell, HCV






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.